{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,21]],"date-time":"2025-08-21T17:49:23Z","timestamp":1755798563050,"version":"3.44.0"},"reference-count":18,"publisher":"SMC Media","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:p>Background:\u00a0Warm autoimmune haemolytic anaemia (wAIHA) is an acquired haemolytic disorder most commonly treated with a combination of corticosteroids, rituximab and\/or splenectomy. Third-line therapies for refractory cases include immunosuppressive agents. Mycophenolate mofetil is frequently used in these scenarios, although its use is supported by small studies and anecdotal evidence rather than large-scale data. Case description:\u00a0We describe three cases of refractory warm autoimmune haemolytic anaemia successfully treated with mycophenolate mofetil. Case 1: A persistent case of autoimmune haemolytic anaemia in a 56-year-old was ultimately managed with mycophenolate mofetil, leading to successful steroid tapering and stable haemoglobin levels without relapse. Case 2: A woman with a complex oncological history, including lymphoma and breast cancer, achieved remission with mycophenolate therapy, maintaining stability post-steroid treatment. Case 3: Mycophenolate proved effective for a 63-year-old with cirrhosis after recurrent autoimmune anaemia and deep vein thrombosis, enabling cessation of steroids and maintaining remission. Conclusion:\u00a0Management of this condition can be challenging and balancing the available treatments is crucial to reduce potential complications from long-term therapies that appear to be ineffective. Our case series demonstrates anecdotal experience on successful use of mycophenolate mofetil for complex refractory cases of wAIHA.<\/jats:p>","DOI":"10.12890\/2024_004780","type":"journal-article","created":{"date-parts":[[2024,8,14]],"date-time":"2024-08-14T03:42:30Z","timestamp":1723606950000},"source":"Crossref","is-referenced-by-count":1,"title":["Mycophenolate mofetil for the treatment of warm autoimmune haemolytic anaemia post-rituximab therapy: a case series"],"prefix":"10.12890","volume":"11","author":[{"given":"Oscar F.","family":"Borja-Montes","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, University of New Mexico School of Medicine, Albuquerque, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alejandro","family":"Toro-Pedroza","sequence":"first","affiliation":[{"name":"Faculty of Health Sciences, Universidad Icesi, Cali, Colombia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Darrell D.","family":"Horton","sequence":"first","affiliation":[{"name":"Department of Pathology, University of New Mexico School of Medicine, Albuquerque, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leslie A.","family":"Andritsos","sequence":"first","affiliation":[{"name":"Hematology and Oncology, UNM Comprehensive Cancer Center, Albuquerque, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ala","family":"Ebaid","sequence":"first","affiliation":[{"name":"Hematology and Oncology, UNM Comprehensive Cancer Center, Albuquerque, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"10397","published-online":{"date-parts":[[2024,8,14]]},"reference":[{"key":"10.12890\/2024_004780_ref1","doi-asserted-by":"crossref","unstructured":"<li>Zanella A, Barcellini W. Treatment of autoimmune hemolytic anemias. <em>Haematologica<\/em> 2014;<strong>99<\/strong>:1547\u20131554.<\/li>","DOI":"10.3324\/haematol.2014.114561"},{"key":"10.12890\/2024_004780_ref2","doi-asserted-by":"crossref","unstructured":"<li>Tranekaer S, Hansen DL, Frederiksen H. Epidemiology of secondary warm autoimmune haemolytic anaemia \u2013 a systematic review and meta-analysis. <em>J Clin Med<\/em> 2021;<strong>10<\/strong>:1244. <\/li>","DOI":"10.3390\/jcm10061244"},{"key":"10.12890\/2024_004780_ref3","doi-asserted-by":"crossref","unstructured":"<li>Park SH. Diagnosis and treatment of autoimmune hemolytic anemia: classic approach and recent advances. <em>Blood Res<\/em> 2016;<strong>51<\/strong>:69\u201371.<\/li>","DOI":"10.5045\/br.2016.51.2.69"},{"key":"10.12890\/2024_004780_ref4","doi-asserted-by":"crossref","unstructured":"<li>Barcellini W, Fattizzo B. How I treat warm autoimmune hemolytic anemia. <em>Blood<\/em> 2021;<strong>137<\/strong>:1283\u20131294. doi: 10.1182\/blood.2019003808. Erratum in: <em>Blood<\/em> 2023;<strong>141<\/strong>:438\u2013439.<\/li>","DOI":"10.1182\/blood.2022019024"},{"key":"10.12890\/2024_004780_ref5","doi-asserted-by":"crossref","unstructured":"<li>Giudice V, Rosamilio R, Ferrara I, Seneca E, Serio B, Selleri C. Efficacy and safety of splenectomy in adult autoimmune hemolytic anemia. <em>Open Med (Wars)<\/em> 2016;<strong>11<\/strong>:374\u2013380.<\/li>","DOI":"10.1515\/med-2016-0068"},{"key":"10.12890\/2024_004780_ref6","doi-asserted-by":"crossref","unstructured":"<li>Michel M. Warm autoimmune hemolytic anemia: advances in pathophysiology and treatment. <em>Presse Med<\/em> 2014;<strong>43<\/strong>:e97\u2013e104.<\/li>","DOI":"10.1016\/j.lpm.2014.02.009"},{"key":"10.12890\/2024_004780_ref7","doi-asserted-by":"crossref","unstructured":"<li>Alba P, Karim MY, Hunt BJ. Mycophenolate mofetil as a treatment for autoimmune haemolytic anaemia in patients with systemic lupus erythematosus and antiphospholipid syndrome. <em>Lupus<\/em> 2003;<strong>12<\/strong>:633\u2013635.<\/li>","DOI":"10.1191\/0961203303lu419cr"},{"key":"10.12890\/2024_004780_ref8","doi-asserted-by":"crossref","unstructured":"<li>Rao VK, Dugan F, Dale JK, Davis J, Tretler J, Hurley JK, et al. Use of mycophenolate mofetil for chronic, refractory immune cytopenias in children with autoimmune lymphoproliferative syndrome. <em>Br J Haematol<\/em> 2005;<strong>129<\/strong>:534\u2013538.<\/li>","DOI":"10.1111\/j.1365-2141.2005.05496.x"},{"key":"10.12890\/2024_004780_ref9","doi-asserted-by":"crossref","unstructured":"<li>J\u00e4ger U, Barcellini W, Broome CM, Gertz MA, Hill A, Hill QA, et al. Diagnosis and treatment of autoimmune hemolytic anemia in adults: recommendations from the First International Consensus Meeting. <em>Blood Rev<\/em> 2020;<strong>41<\/strong>:100648.<\/li>","DOI":"10.1016\/j.blre.2019.100648"},{"key":"10.12890\/2024_004780_ref10","doi-asserted-by":"crossref","unstructured":"<li>Braendstrup P, Bjerrum OW, Nielsen OJ, Jensen BA, Clausen NT, Hansen PB, et al. Rituximab chimeric anti-CD20 monoclonal antibody treatment for adult refractory idiopathic thrombocytopenic purpura. <em>Am J Hematol<\/em> 2005;<strong>78<\/strong>:275\u2013280.<\/li>","DOI":"10.1002\/ajh.20276"},{"key":"10.12890\/2024_004780_ref11","doi-asserted-by":"crossref","unstructured":"<li>Cavallaro F, Barcellini W, Fattizzo B. Antibody based therapeutics for autoimmune hemolytic anemia. <em>Expert Opin Biol Ther<\/em> 2023;<strong>23<\/strong>:1227\u20131237.<\/li>","DOI":"10.1080\/14712598.2023.2274912"},{"key":"10.12890\/2024_004780_ref12","doi-asserted-by":"crossref","unstructured":"<li>Fattizzo B, Bortolotti M, Giannotta JA, Zaninoni A, Consonni D, Barcellini W. Intravascular hemolysis and multitreatment predict thrombosis in patients with autoimmune hemolytic anemia. <em>J Thromb Haemost<\/em> 2022;<strong>20<\/strong>:1852\u20131858.<\/li>","DOI":"10.1111\/jth.15757"},{"key":"10.12890\/2024_004780_ref13","doi-asserted-by":"crossref","unstructured":"<li>Ahlmann M, Hempel G. The effect of cyclophosphamide on the immune system: implications for clinical cancer therapy. <em>Cancer Chemother Pharmacol<\/em> 2016;<strong>78<\/strong>:661\u2013671.<\/li>","DOI":"10.1007\/s00280-016-3152-1"},{"key":"10.12890\/2024_004780_ref14","doi-asserted-by":"crossref","unstructured":"<li>Bobadilla NA, Gamba G. New insights into the pathophysiology of cyclosporine nephrotoxicity: a role of aldosterone. <em>Am J Physiol Renal Physiol<\/em> 2007;<strong>293<\/strong>:F2\u2013F9.<\/li>","DOI":"10.1152\/ajprenal.00072.2007"},{"key":"10.12890\/2024_004780_ref15","doi-asserted-by":"crossref","unstructured":"<li>Howard J, Hoffbrand AV, Prentice HG, Mehta A. Mycophenolate mofetil for the treatment of refractory auto-immune haemolytic anaemia and auto-immune thrombocytopenia purpura. <em>Br J Haematol<\/em> 2002;<strong>117<\/strong>:712\u2013715. <\/li>","DOI":"10.1046\/j.1365-2141.2002.03430.x"},{"key":"10.12890\/2024_004780_ref16","doi-asserted-by":"crossref","unstructured":"<li>Alba P, Karim MY, Hunt BJ. Mycophenolate mofetil as a treatment for autoimmune haemolytic anaemia in patients with systemic lupus erythematosus and antiphospholipid syndrome. <em>Lupus<\/em> 2003;<strong>12<\/strong>:633\u2013635. <\/li>","DOI":"10.1191\/0961203303lu419cr"},{"key":"10.12890\/2024_004780_ref17","doi-asserted-by":"crossref","unstructured":"<li>Kotb R, Pinganaud C, Trichet C, Lambotte O, Dreyfus M, Delfraissy JF, et al. Efficacy of mycophenolate mofetil in adult refractory auto-immune cytopenias: a single center preliminary study. <em>Eur J Haematol<\/em> 2005;<strong>75<\/strong>:60\u201364. <\/li>","DOI":"10.1111\/j.1600-0609.2005.00437.x"},{"key":"10.12890\/2024_004780_ref18","doi-asserted-by":"crossref","unstructured":"<li>O\u2019Connell N, Goodyer M, Gleeson M, Storey L, Williams M, Cotter M, et al. Successful treatment with rituximab and mycophenolate mofetil of refractory autoimmune hemolytic anemia post-hematopoietic stem cell transplant for dyskeratosis congenita due to TINF2 mutation. <em>Pediatr Transplant<\/em> 2014;<strong>18<\/strong>: E22-24.<\/li>","DOI":"10.1111\/petr.12172"}],"container-title":["European Journal of Case Reports in Internal Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.ejcrim.com\/index.php\/EJCRIM\/article\/download\/4780\/4210","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.ejcrim.com\/index.php\/EJCRIM\/article\/download\/4780\/4211","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.ejcrim.com\/index.php\/EJCRIM\/article\/download\/4780\/4211","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,19]],"date-time":"2025-08-19T10:14:31Z","timestamp":1755598471000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ejcrim.com\/index.php\/EJCRIM\/article\/view\/4780"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,14]]},"references-count":18,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.12890\/2024_004780","relation":{"has-manifestation":[{"id-type":"other","id":"1-117-4780-g4210","asserted-by":"subject"},{"id-type":"other","id":"1-117-4780-g4211","asserted-by":"subject"}],"is-part-of":[{"id-type":"other","id":"1-117","asserted-by":"subject"}]},"ISSN":["2284-2594"],"issn-type":[{"type":"electronic","value":"2284-2594"}],"subject":[],"published":{"date-parts":[[2024,8,14]]}}}